Daiichi Sankyo and Merck withdrew a lung cancer antibody-drug conjugate filing after FDA pushback, according to the report. The regulator said the companies lacked sufficient data to support accelerated approval in the targeted lung cancer population, dealing a fresh blow to a previously announced $4 billion deal.